MedPath

Irreversible Electroporation Ablation for Colorectal Metastases to the Lung

Not Applicable
Completed
Conditions
Colorectal Metastases to the Lung
Interventions
Device: Irreversible Electroporation Ablation
Registration Number
NCT02461550
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Brief Summary

The investigators are investigating the use of a new cancer treatment called Irreversible Electroporation (IRE). This treatment delivers electrical energy between two needles placed in a cancer. The electrical energy causes cells to die. While this has been used in patients for different applications, the investigators are trying to understand how safe and well it works in colon cancer that has spread to the lung. Once the irreversible electroporation procedure is completed during the operation, the surgeon will then remove the cancer according to standard procedure. As part of the study, they will be measuring safety of the electrical energy delivered and will be reviewing the resected specimen under the microscope.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2
Inclusion Criteria
  • Diagnosed Colorectal cancer with oligometastatic colorectal cancer in the lung
  • Lung lesion size is greater than 1 cm
  • Patient will undergo surgical resection as per consultation with their thoracic surgeon and medical oncologist
  • Patient is cleared to undergo paralytic anesthesia.
  • Patients 18 years old and older
Read More
Exclusion Criteria
  • Patients with history of cardiac dysrhythmia
  • Known heart failure (EF < 40%)
  • Pacemaker/defibrillator
  • Patient's with any metallic cardiac implant
  • Patient on anti-coagulation therapy and are unable to stop therapy for the perioperative period
  • Women who are pregnant and/or nursing
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
IRE procedureIrreversible Electroporation AblationThe IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
Primary Outcome Measures
NameTimeMethod
The Frequency of Adverse Events2 years

Safety will be measured by using the NCI Common Terminology Criteria for Adverse Events (CTCAE v4.0). The goal of this study is to establish safety.

If there are 3 or more grade 3 or higher device related AEs, then we will stop the study.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (4)

Memorial Sloan-Kettering at Basking Ridge

🇺🇸

Basking Ridge, New Jersey, United States

Memorial Sloan-Kettering Cancer Center @ Suffolk

🇺🇸

Commack, New York, United States

Memorial Sloan Kettering West Harrison

🇺🇸

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath